TWiV 686: COVID-19 clinical update #38 with Dr. Daniel Griffin

November 28, 2020

Daniel Griffin provides his weekly clinical report on COVID-19, including new post-exposure guidelines from CDC, clinical trials of Remdesivir and convalescent plasma, FDA EUA for baricitinib and Regeneron’s monoclonal antibody and more.

Hosts: Daniel Griffin and Vincent Racaniello

Click arrow to play
Download TWiV 686 (21 MB .mp3, 35 min)
Subscribe (free): iTunesGoogle PodcastsRSSemail

Become a patron of TWiV!

Links for this episode

Intro music is by Ronald Jenkees

Send your virology questions and comments to

Leave a Reply

Your email address will not be published. Required fields are marked *

2 comments on “TWiV 686: COVID-19 clinical update #38 with Dr. Daniel Griffin

  1. Richard Cornell Nov 28, 2020

    On a local PBS program a Professor from a university was ask why so many people of her hue do not believe that this plague is a plague and continue to bunch up.
    Her answer was because it is the government that is telling them and no one trust the government.
    Sad that so many need not die from this virus, but again until it hits your family this plague someone else’s problem.
    This podcast is still preaching to the choir and unless it becomes a standard message to every one only those interest will see and hear it.

  2. Jeffery Biss Nov 29, 2020

    At 11:50 Dr. Griffin starts talking about quarantining. He states that 2-14 days after exposure you could get sick but we now know that testing can pick up that you will get sick 2-3 days before you get sick. But how does anyone know that they were exposed, especially if the infected person is asymptomatic? It seems that one may never know what “post exposure” is. Therefore, shouldn’t the indications be early symptoms, such as loss of smell, Shortness of breath or difficulty breathing, Muscle aches, Chills, Sore throat, Runny nose, Headache, Chest pain, Pink eye (from

    If these symptoms appear 2-14 days from exposure and one doesn’t know that they were exposed, then it seems that the discussion should be around the first sign of symptoms, which would align with what Dr. Griffin discussed.